DarioHealth Corp.
DarioHealth Corp. builds digital health and chronic-condition management solutions that combine self-care apps, coaching, analytics, and connected devices for employers, health plans, and pharmaceutical companies. The company grew out of direct-to-consumer digital health and now sells a broader AI-driven platform through B2B and B2B2C channels, with a growing focus on behavioral health, cardiometabolic care, and medication support.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDigital programs for diabetes, hypertension, weight management, and related conditions.
Mental health and engagement tools sold to health plans, employers, and members.
Enterprise deployments for self-insured employers, health plans, and benefit administrators.
Patient education, adherence support, and journey analytics for drug makers.
Consumer-facing self-care offerings used as an innovation and testing channel.
Products
Reported · share of revenue- Services66.8 %
- Hardware and Consumable Products33.2 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The core buyers are health plans, self-insured employers, benefit administrators, and pharmaceutical companies that want measurable engagement and lower healthcare costs. The company also serves consumers directly in the U.S., but management says the B2B and B2B2C channels now represent most revenue. Recent disclosures highlight traction with large national health plans, major employers, and a dozen global pharmaceutical companies.
Buy member-facing digital health and behavioral health programs to improve engagement and outcomes.
Purchase chronic condition and wellness solutions to reduce claims costs and improve productivity.
Use the platform for patient education, adherence support, and journey analytics.
Adopt the platform for employee health programs and cost containment.
Use self-care tools and digital coaching, mainly as a product development and engagement channel.
Strategy
Management is pushing the business from a D2C origin toward scaled enterprise distribution through employers, health plans, benefit administrators, and pharma partners. The current strategy emphasizes integrated chronic care, behavioral health, and GLP-1 support, backed by clinical research and AI personalization to improve outcomes and justify ROI. The company is also using partnerships and new client wins to broaden its customer base and reduce dependence on any single account.
Enterprise and partner channels now drive most revenue and offer larger, repeatable contracts.
Employers and payers want tools that improve outcomes and help manage expensive therapies.
Revenue concentration with a major customer creates downside if that relationship weakens.
Geography
DarioHealth is headquartered in the United States and generates most of its commercial activity there, including employer, health plan, and consumer deployments. The company also has significant operational exposure to Israel, where some principal executive officers and other operations are located, and it sources some medical devices and hardware components from China. That mix creates both market concentration in the U.S. and supply-chain and geopolitical exposure abroad.
Risks
The company faces customer concentration risk, since a major customer still represents a meaningful share of revenue and receivables. It also has supply-chain and execution risk from tariff exposure and China-sourced hardware components, plus covenant and financing risk after missing a debt covenant and relying on lender discussions and potential equity cure. As a digital health business, it also depends on continued employer and payer adoption, clinical evidence, and stable reimbursement and procurement behavior.
- Debt covenant breachImpact: HighLikelihood: High
The company did not meet one financial covenant and may need waivers, amendments, or an equity cure to avoid worse financing terms.
Exposure: Credit Agreement with up to $50 million facility
- Customer concentrationImpact: High
A major customer still accounts for a meaningful share of revenue and receivables, so loss or underperformance would reduce sales quickly.
Exposure: One customer accounted for 10.6% of six-month revenue and 16.4% of receivables
- Tariff and supply-chain disruptionImpact: MediumLikelihood: High
Some medical devices and hardware components are manufactured in China, making the business vulnerable to trade policy changes and sourcing delays.
Exposure: Hardware sourcing and partner-side implementation
- Nasdaq listing and stock volatilityImpact: MediumLikelihood: High
Low share price and extreme volatility can restrict access to capital and increase financing uncertainty.
Exposure: Nasdaq bid-price compliance and market perception
- Geopolitical exposure in IsraelImpact: MediumLikelihood: Medium
Principal executive officers and significant operations are in Israel, so conflict or instability could disrupt operations and execution.
Exposure: Management and operating footprint
Accounting
Judgemental itemsEnterprise and partner contracts may recognize revenue over time as services are delivered, so onboarding delays can shift quarterly results.
Impact: Quarterly revenue comparability
The Twill acquisition adds amortization and integration costs that affect gross margin and operating loss trends.
Impact: Reported profitability
Changes in warrant valuation can create large non-cash gains or losses below operating income.
Impact: Net income volatility
Equity awards are a meaningful part of compensation and can materially inflate operating expenses.
Impact: G&A and operating loss
Covenant breaches can trigger higher interest, waivers, or refinancing needs and affect going-forward liquidity assumptions.
Impact: Financing costs and liquidity
Similar listed companies
Publicly listed companies with a comparable business focus.
Syra Health Corp
SYRA · Services-Employment Agencies
Syra Health Corp is a U.S.-based healthcare services company organized around workforce staffing, population health, and behavioral and mental health offerings.
DexCom, Inc
DXCM · Surgical & Medical Instruments & Apparatus
DexCom is a U.S.
Gaxos.ai Inc
GXAI · Services-Prepackaged Software
Eli Lilly and Company
LLY · Pharmaceutical Preparations
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products, with a portfolio anchored by diabetes, obesity, oncology, immunology, and neuroscience medicines.
Definitive Healthcare Corp.
DH · Services-Prepackaged Software
MedWellAI, Inc.
MWAI · Finance Services
Last updated: 24/09/2026